Licensing model pays off for Biocon
INDIA INC ON BUYING SPREE

WebinarsNew
Deep DiveNew
Explore Business Standard
INDIA INC ON BUYING SPREE

| At present, the company has about 12 molecules that have the potential to be out-licensed and fetch the company substantial revenues over the next two years."We see licensing as a strong affirmation of our innovation-led business strategy and expect to realise even greater licensing revenues in the future," Biocon CMD Kiran Mazumdar-Shaw said. |
First Published: Jul 19 2007 | 12:00 AM IST